Acute renal failure with the combined use of rosuvastatin and fenofibrate

Autor:	Yusuf Sezen, Hakan Buyukhatipoglu, Unal Guntekin, Idris Kirhan, Omer Faruk Dag
Rok vydání:	2010
Předmět:	Adult medicine.medical_specialty Statin medicine.drug_class Fibrate Pharmacology Critical Care and Intensive Care Medicine Fenofibrate Internal medicine medicine Humans Rosuvastatin Drug Interactions Rosuvastatin Calcium Adverse effect Hypolipidemic Agents Sulfonamides business.industry General Medicine Acute Kidney Injury Discontinuation Fluorobenzenes Regimen Pyrimidines Nephrology Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug
Zdroj:	Renal failure. 32(5)
ISSN:	1525-6049
Popis:	Among the lipid-lowering drugs, the statins and fibrates are the most commonly used agents. Either class of drug is considered relatively safe. Though a variety of albeit uncommon adverse side effects have been observed with both classes, most of these therapeutic complications can be managed without discontinuation of the offending drug. Sometimes, especially in patients with extremely high cholesterol and/or triglyceride levels, a combination regimen is deemed necessary. However, the combined use of lipid-lowering drugs increases the incidence and severity of adverse events. In this article, we report an unusual case of acute renal failure (ARF) in a patient who had been prescribed both a statin (rosuvastatin) and a fibrate (fenofibrate).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80f2800e2f80f954e262faaa32253f59 https://pubmed.ncbi.nlm.nih.gov/20486848 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.